Medication Treatments for Opioid Use Disorder: What Is the Impact on Mood and Mood Disorders?

被引:0
|
作者
Hassan A.N. [1 ,2 ]
Nunes E. [3 ]
机构
[1] Addictions Division, Centre for Addiction and Mental Health, 100 Stokes Street, Toronto, M6J 1H4, ON
[2] Department of Psychiatry, University of Toronto, Toronto
[3] Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY
关键词
Anxiety; Depression; Mood; Opioid agonist therapy; Opioid medication; Opioid use disorder;
D O I
10.1007/s40429-018-0215-x
中图分类号
学科分类号
摘要
Purpose of Review: There has been an interest in evaluating the effect of opioid medications on mood in patients with or without opioid use disorder (OUD) because of potential mechanistic relationships between the opioid system and mood. In this review, we will summarize the prospective clinical trials that used opioid medications (naltrexone, methadone, and buprenorphine) to evaluate the effect on mood and anxiety in patients with and without OUD. Findings: Buprenorphine and buprenorphine/samidorphan combination have shown promising short-term effect for depressed patients without OUD but the effects are modest. Naltrexone does not worsen mood in patients with OUD and is in fact associated with improved mood for adherent patients. Methadone and buprenorphine treatment for OUD are both associated with substantial improvements in mood. Implications: Buprenorphine or buprenorphine combined with a mu receptor antagonist may be effective for treatment-resistant depression among patients without OUD, and large randomized controlled trials with longer trial lengths are needed to further evaluate this effect. Among patients with OUD, effective medication treatment for the OUD is the priority, and with any opioid medication mood often improves. © 2018, Springer International Publishing AG, part of Springer Nature.
引用
收藏
页码:303 / 311
页数:8
相关论文
共 50 条
  • [1] What is the place of psychological treatments in mood disorders?
    Parker, Gordon
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2007, 10 (01): : 137 - 145
  • [2] Activity space during treatment with medication for opioid use disorder: Relationships with personality, mood, and drug use
    Panlilio, Leigh, V
    Burgess-Hull, Albert J.
    Feldman, Jeffrey D.
    Rogers, Jeffrey M.
    Tyburski, Matthew
    Smith, Kirsten E.
    Epstein, David H.
    [J]. JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2024, 157
  • [3] What is the impact of pelvic disorders on female mood?
    Illiano, Ester
    Balzarro, Matteo
    Marchesi, Alessandro
    Rubilotta, Emanuele
    Costantini, Elisabetta
    [J]. NEUROUROLOGY AND URODYNAMICS, 2019, 38 : S23 - S25
  • [4] Somatic Treatments for Mood Disorders
    Rosa, Moacyr A.
    Lisanby, Sarah H.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2012, 37 (01) : 102 - 116
  • [5] Somatic Treatments for Mood Disorders
    Moacyr A Rosa
    Sarah H Lisanby
    [J]. Neuropsychopharmacology, 2012, 37 : 102 - 116
  • [6] Treatment of Tobacco Use Disorder and Mood Disorders in Adolescents
    Witt D.R.
    Patten C.A.
    [J]. Current Addiction Reports, 2018, 5 (3) : 346 - 358
  • [7] COMORBIDITY OF SUBSTANCE USE DISORDER AND SCHIZOPHRENIA AND MOOD DISORDERS
    Delafariban, M.
    [J]. EUROPEAN PSYCHIATRY, 2011, 26
  • [8] Mood stabilizing effects of methadone in Opioid Use Disorder patient
    Gohari, Jacob
    Riaz, Usman
    [J]. HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, 2020, 22 (01) : 7 - 8
  • [9] Impact of Mood Disorders
    Wagner, Karen Dineen
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2011, 72 (03) : 376 - 377
  • [10] Mood disorders: Systematic medication management
    Young, AH
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 1999, 175 : 98 - 98